| Literature DB >> 27777969 |
Vidya A Holla1, L K Chatra2, Prashanth Shenai2, Devika Shetty1, Ashwini Baliga1.
Abstract
Aim and Objectives. Oral submucous fibrosis (OSF) is a potentially malignant disorder associated with the usage of areca nut. Usage of processed forms of areca nut is popular among the youth and its carcinogenic effects are not well known. Due to large immigrant population, various patterns of areca nut usage are seen. The aim of this study is to assess the various quid chewing patterns and their association with severity of OSF. Materials and Methods. A cross-sectional study was carried out with 250 cases clinically and histologically diagnosed as having OSF lesion that were selected and subjected to a detailed habit history which was recorded through preformed questionnaire. The data obtained was statistically analyzed. Results. Among the 250 subjects, males were seen to be affected more than females within the age group of 26-35 years and were having clinical stage I OSF. A combination of processed areca nut and processed tobacco was used by the majority of the subjects with duration of 1 to 5 years, at a frequency of 3 to 5 quids per day. Conclusion. The present study confirms the association between oral submucous fibrosis and the quid containing processed areca nut and processed tobacco and also highlights the increasing youth population using the processed forms of areca nut.Entities:
Year: 2016 PMID: 27777969 PMCID: PMC5061949 DOI: 10.1155/2016/6124059
Source DB: PubMed Journal: Adv Med ISSN: 2314-758X
Haider et al. clinically graded OSF into the following.
| Stage I | Faucial bands only |
| Stage II | Faucial and buccal bands |
| Stage III | Faucial, buccal, and labial bands |
Figure 1Gender distribution.
Figure 2Age distribution.
Figure 3Cases distributed based on clinical staging.
Distribution of cases based on the type of quid.
| Type of quid | Composition of the quid | Number of patients | Percentage |
|---|---|---|---|
| Traditional forms | |||
| Type I | Betel leaf and areca nut | None | None |
| Type II | Betel leaf, areca nut and slacked lime | 14 | 5.6% |
| Type III | Betel leaf, areca nut, lime, and tobacco | 18 | 7.2% |
|
| |||
| Processed forms | |||
| Type IV | Processed areca nut | 76 | 30.4% |
| Type V | Processed areca nut and processed tobacco | 98 | 39.2% |
|
| |||
| Type VI | Combined quid usage | 44 | 17.6% |
Association between the type of quid and clinical staging.
| Quid | Stage | ||
|---|---|---|---|
| I | II | III | |
| Betel leaf and areca nut (0) | — | — | — |
| Betel leaf, areca nut, and slacked | 12 (85.71%) | 2 (14.28%) | 0 |
| Betel leaf, areca nut, lime, and tobacco (18) | 12 (66.66%) | 6 (33.33%) | 0 |
| Processed areca nut (76) | 44 (57.89%) | 24 (31.57%) | 8 (10.52%) |
| Processed areca nut and processed tobacco (98) | 42 (42.85%) | 42 (42.85%) | 14 (14.28%) |
| Combined quid usage (44) | 22 (50%) | 20 (45.45%) | 2 (4.54%) |
χ 2 = 16.64; p = 0.034 SIG.
Clinical stage I and frequency.
| 1-2/day | 3–5/day | 6–10/day | >10/day | |
|---|---|---|---|---|
| Type I | 0 | 0 | 0 | 0 |
| Type II | 6 (4.5%) | 6 (4.5%) | 0 | 0 |
| Type III | 4 (3%) | 4 (3%) | 4 (3%) | 0 |
| Type IV | 4 (3%) | 26 (19.6%) | 10 (7.5%) | 4 (3%) |
| Type V | 6 (4.5%) | 16 (12.12%) | 16 (12.12%) | 2 (1.5%) |
| Combined | 4 (3%) | 16 (12.12%) | 2 (1.5%) | 0 |
χ 2 = 25.537; p = 0.0135 SIG.
Clinical stage I and duration.
| 1–12 months | 1–5 years | 5–10 years | >10 years | |
|---|---|---|---|---|
| Type I | 0 | 0 | 0 | 0 |
| Type II | 4 (3.0%) | 0 | 2 (1.5%) | 6 (4.5%) |
| Type III | 4 (3.0%) | 0 | 2 (1.5%) | 6 (4.5%) |
| Type IV | 14 (10.6%) | 26 (19.6%) | 2 (1.5%) | 2 (1.5%) |
| Type V | 10 (7.5%) | 24 (18.18%) | 8 (6.0%) | 0 |
| Combined | 2 (1.5%) | 12 (9.0%) | 4 (3.0%) | 4 (3.0%) |
χ 2 = 53.504; p < 0.001 VHS.
Clinical stage II and frequency.
| 1 to 2/day | 3 to 5/day | 6–10/day | >10/day | |
|---|---|---|---|---|
| Type I | 0 | 0 | 0 | 0 |
| Type II | 0 | 0 | 2 | 0 |
| Type III | 0 | 2 (2.12%) | 2 (2.12%) | 2 (2.12%) |
| Type IV | 2 (2.12%) | 12 (12.76%) | 8 (8.55%) | 2 (2.12%) |
| Type V | 2 (2.12%) | 18 (19.14%) | 12 (12.76%) | 8 (8.55%) |
| Combined | 0 | 8 (8.55%) | 6 (6.3%) | 6 (6.3%) |
χ 2 = 12.89; p = 0.1675 NS.
Clinical stage II and duration.
| 1–12 months | 1–5 years | 5–10 years | >10 years | |
|---|---|---|---|---|
| Type I | 0 | 0 | 0 | 0 |
| Type II | 0 | 2 (2.12%) | 0 | 0 |
| Type III | 0 | 2 (2.12%) | 2 (2.12%) | 2 (2.12%) |
| Type IV | 2 (2.12%) | 22 (23.4%) | 0 | 0 |
| Type V | 8 (8.5%) | 24 (25.53%) | 8 (8.5%) | 2 (2.12%) |
| Combined | 0 | 8 (8.5%) | 10 (10.6%) | 2 (2.12%) |
χ 2 = 30.692; p < 0.001 VHS.
Clinical stage III and frequency.
| 1 to 2/day | 3 to 5/day | 6–10/day | >10/day | |
|---|---|---|---|---|
| Type I | 0 | 0 | 0 | 0 |
| Type II | 0 | 0 | 0 | 0 |
| Type III | 0 | 0 | 0 | 0 |
| Type IV | 0 | 4 (16.6%) | 2 (8.3%) | 2 (8.3%) |
| Type V | 0 | 4 (16.6%) | 6 (25.0%) | 4 (16.6%) |
| Combined | 0 | 0 | 0 | 2 (8.3%) |
χ 2 = 5.571; p = 0.2335 NS.
Clinical stage III and duration.
| 1–12 months | 1–5 year | 5–10 year | >10 years | |
|---|---|---|---|---|
| Type I | 0 | 0 | 0 | 0 |
| Type II | 0 | 0 | 0 | 0 |
| Type III | 0 | 0 | 0 | 0 |
| Type IV | 2 (8.3%) | 2 (8.3%) | 2 (8.3%) | 2 (8.3%) |
| Type V | 0 | 8 (33.33%) | 4 (16.6%) | 2 (8.3%) |
| Combined | 0 | 2 (8.3%) | 0 | 0 |
χ 2 = 1.979; p = 0.739 NS.